Mita S, Monnat R J, Loeb L A
Joseph Gottstein Memorial Cancer Research Laboratory, Department of Pathology, University of Washington, Seattle 98195.
Cancer Res. 1988 Aug 15;48(16):4578-83.
The mutagenic potentials of ethylmethane sulfonate, N-methyl-N'-nitrosoguanidine, and benzo(a)pyrene diol-epoxide in human mitochondria were determined by cloning and nucleotide sequencing of mitochondrial (mt) DNA from HeLa cells treated with these mutagens. Mutagen concentrations that reduced cell survival to approximately 0.1% of untreated cultures were used. Mitochondrial DNA was prepared 2 to 3 weeks after mutagen treatment, at which time the treated cell population had regrown to 10 times the starting cell number. In one series of experiments, a portion of the D-loop region of mtDNA from treated or control HeLa cells was cloned into the bacteriophage vector M13mp19, and the nucleotide sequences of 102 independent clones were determined. Only a single G:C base pair deletion was observed in 1 of 12 clones derived from HeLa cells treated 6 times with ethylmethane sulfonate. From benzo(a)pyrene diol-epoxide-treated HeLa cells, G:C base pair deletions were found in 14 of 63 clones. All 14 of these G:C deletion mutations occurred at the same position in independent clones, however, and thus could be the progeny of a single mutational event. In a second series of experiments, a method for the selection of mtDNA mutants was utilized. Mutations in an "uncloneable" fragment of human mtDNA render the fragment cloneable and thus provide a selection for mutations in this region of human mtDNA. No enhancement in the cloning efficiency of this region of mtDNA was observed after exposure of cells to toxic concentrations of either MNNG or benzo(a)pyrene diol-epoxide. Moreover, the site and types of nucleotide sequence alterations observed after mutagen treatment were similar to those obtained in the absence of drug treatment. The results of both types of experiments suggest that mutagenesis of human mtDNA is an infrequent event, even after extensive treatment of HeLa cells with potent mutagens that can covalently modify mtDNA.
通过对用这些诱变剂处理的HeLa细胞的线粒体(mt)DNA进行克隆和核苷酸测序,测定了甲磺酸乙酯、N-甲基-N'-亚硝基胍和苯并(a)芘二醇环氧化物对人线粒体的诱变潜力。使用能将细胞存活率降低至未处理培养物的约0.1%的诱变剂浓度。在诱变剂处理后2至3周制备线粒体DNA,此时处理后的细胞群体已生长至起始细胞数的10倍。在一系列实验中,将来自处理过的或对照HeLa细胞的mtDNA的D环区域的一部分克隆到噬菌体载体M13mp19中,并测定了102个独立克隆的核苷酸序列。在用甲磺酸乙酯处理6次的HeLa细胞衍生的12个克隆中,仅在1个克隆中观察到单个G:C碱基对缺失。在苯并(a)芘二醇环氧化物处理的HeLa细胞中,在63个克隆中的14个中发现了G:C碱基对缺失。然而,所有这14个G:C缺失突变都发生在独立克隆的同一位置,因此可能是单个突变事件的后代。在第二系列实验中,采用了一种选择mtDNA突变体的方法。人mtDNA“不可克隆”片段中的突变使该片段可克隆,从而为该区域的人mtDNA突变提供了一种选择。在用MNNG或苯并(a)芘二醇环氧化物的毒性浓度处理细胞后,未观察到该区域mtDNA克隆效率的提高。此外,诱变剂处理后观察到的核苷酸序列改变的位点和类型与未进行药物处理时获得的相似。两种类型实验的结果均表明,即使在用能共价修饰mtDNA的强效诱变剂对HeLa细胞进行广泛处理后,人mtDNA的诱变也是罕见事件。